Challenges in Bulk Drug Substance Management
July 31, 2020
Biopharma Insights—Thought Leadership from Marketers | Paid Program
Final liquid drug substance production and fill–finish activities rarely occur at the same site. Nearly all pharmaceutical and biotechnology companies outsource a portion of their fill–finish needs to contract manufacturing organizations (CMOs) to help them address unexpected demand, satisfy second source policies, or better match scale with need.